| Abstrakt: |
A recent study conducted by researchers at the University of Bari in Italy explored the impact of treating Small Airways Disease (SAD) in patients with severe asthma. The study found that transitioning patients from separate inhalers to a single-inhaler triple therapy resulted in significant improvements in respiratory symptoms, lung function, and airway inflammation. The researchers concluded that this approach, known as target-therapy, can enhance clinical control and small airway function in patients with severe asthma, potentially achieving a stable state called "Quiet Asthma." This research provides valuable insights into the management of asthma and may help avoid or delay the use of biological therapy. [Extracted from the article] |
